© 2021 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
We have a powerful purpose in going beyond the ordinary to make a meaningful impact in rare patients’ lives. That’s why we come to work every day.
Peter Heerma has served as chief commercial officer at Travere Therapeutics since October 2019. He is responsible for leading the company’s commercial organization including commercialization strategy for approved products and pre-commercial planning for pipeline programs. He brings more than 20 years of global experience launching best-in-class therapies across therapeutic areas, managing pipeline and on-market product portfolios, and leading commercial and cross-functional teams at a number of top biopharmaceutical organizations.
Prior to joining Travere Therapeutics, Mr. Heerma served as global product general manager for oncology and cardiovascular products at Amgen where he led four cross-functional global product leadership teams with a revenue base exceeding $7 billion in 2018. He has also held various commercial leadership roles at AbbVie and Abbott Laboratories, most recently serving as AbbVie’s senior director of portfolio strategy for hepatology and nephrology. Prior to that, he served as senior director and asset team lead for HCV, diabetic nephropathy, and neuroscience development projects at AbbVie. While at Abbott Laboratories, Mr. Heerma held the titles of director of commercial strategy for renal care, international marketing director for Zemplar, business unit manager of hospital products, and product manager for obesity and cardiovascular products.
He holds a Master of Science in European business administration and business law from the Lund University in Sweden and a Bachelor of Science in retail management and marketing from Stenden University in the Netherlands.